Benzinga · Aug 28, 2026
BioXcel Stock Plunges: Chapter 11 Filing Triggers Teva Stalking Horse Bid
BioXcel Chapter 11 sends BTAI shares sharply lower as Teva becomes the stalking horse bidder for IGALMI and BXCL501 assets.
TE
NYSE · TEVA
Teva Pharmaceutical Industries Limited
Healthcare · Drug Manufacturers - Specialty & Generic
$36.44
Down-$0.52 (-1.41%)
Updated Aug 31, 2026, 3:35 PM
SID Score
6.7/10
Composite research score
Smart Money
60/100
Neutral
- Market cap
- 34.61B
- P/E ratio
- -217.43
- Dividend yield
- 0.00%
- 52-week range
- $17.94 – $38.37
- Volume
- 3.14M
- Avg. volume
- 11.34M
Price performance
TEVA price history
1M range · 20 trading sessions · Daily adjusted prices
TEVA closed at $36.44 after 20 trading sessions, up 5.75% for the selected period.
- Last close
- $36.44
- Period change
- +5.75%
- Period low
- $34.43
- Period high
- $38.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $37.37 | $37.42 | $36.37 | $36.44 | 3.14M |
| Aug 27, 2026 | $37.72 | $38.37 | $37.535 | $37.62 | 4.72M |
| Aug 26, 2026 | $37.70 | $38.055 | $37.07 | $37.92 | 4.82M |
| Aug 25, 2026 | $37.13 | $38.11 | $37.09 | $38.10 | 5.28M |
| Aug 24, 2026 | $37.30 | $37.32 | $36.75 | $36.93 | 3.34M |
| Aug 21, 2026 | $36.79 | $37.75 | $36.65 | $37.34 | 4.3M |
| Aug 20, 2026 | $37.12 | $37.345 | $36.735 | $36.81 | 4.51M |
| Aug 19, 2026 | $37.00 | $37.83 | $36.6034 | $37.47 | 7.98M |
| Aug 18, 2026 | $36.47 | $37.25 | $36.34 | $36.58 | 6.2M |
| Aug 17, 2026 | $36.53 | $36.78 | $35.99 | $36.46 | 3.58M |
| Aug 14, 2026 | $36.26 | $36.81 | $36.0906 | $36.77 | 2.33M |
| Aug 13, 2026 | $36.90 | $37.389 | $36.46 | $36.52 | 7.61M |
| Aug 12, 2026 | $36.80 | $37.24 | $36.44 | $36.74 | 5.7M |
| Aug 11, 2026 | $36.17 | $36.98 | $36.13 | $36.48 | 8.04M |
| Aug 10, 2026 | $35.03 | $36.14 | $35.00 | $36.14 | 5.61M |
| Aug 7, 2026 | $35.00 | $35.77 | $34.87 | $35.36 | 4.27M |
| Aug 6, 2026 | $34.54 | $34.92 | $34.38 | $34.81 | 4.13M |
| Aug 5, 2026 | $34.25 | $34.98 | $33.89 | $34.72 | 4.96M |
| Aug 4, 2026 | $34.62 | $34.6492 | $34.05 | $34.43 | 4.92M |
| Aug 3, 2026 | $35.00 | $35.07 | $33.7804 | $34.46 | 6.21M |
Latest TEVA news
The latest Smart Investors Daily articles mentioning TEVA.
Stock researchCompany · Overview
TEVA research
Overview
Company profile and research snapshot.
Company profile
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $32.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 25, 2020 | Oppenheimer | Perform | — |
| Nov 6, 2020 | BMO Capital | Market Perform | — |
| Aug 6, 2020 | SVB Leerink | Market Perform | — |
| Aug 6, 2020 | Barclays | Equal-Weight | — |
| Jul 27, 2020 | Goldman Sachs | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 28, 2026
BioXcel Therapeutics Kicks Off DoD-Funded Phase 2a Study Of BXCL501 For Acute Stress Reactions, Led By UNC Institute For Trauma Recovery
Benzinga · Aug 26, 2026
Major Update: Amir Weiss At Teva Pharmaceutical Indus Exercises Options, Realizing $46K
A large exercise of company stock options by Amir Weiss, Chief Accounting Officer at Teva Pharmaceutical Indus (NYSE:TEVA) was disclosed in a new SEC filing on August 25, as part of an insider exercise. What Happened: A
SeekingAlpha · Aug 20, 2026
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
Alvotech stock outlook: Hold rating after missed H1 2026 earnings and FDA CRLs; biosimilar pipeline targets Q4 2026. Click for this ALVO update.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
